Ultragenyx: Q2 Earnings Snapshot

By The Associated Press
August 4, 2026 | 4:57 PM

NOVATO, Calif. (AP) — NOVATO, Calif. (AP) — Ultragenyx Pharmaceutical Inc. (RARE) on Tuesday reported a loss of $92 million in its second quarter.

On a per-share basis, the Novato, California-based company said it had a loss of 90 cents.

The results beat Wall Street expectations. The average estimate of seven analysts surveyed by Zacks Investment Research was for a loss of $1.27 per share.

The biotechnology company posted revenue of $214 million in the period, also exceeding Street forecasts. Five analysts surveyed by Zacks expected $181 million.

_____

This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on RARE at https://www.zacks.com/ap/RARE

California couple and their surrogate testify in Texas court as dispute over newborn escalates

By The Associated Press
August 25, 2026 | 7:59 PM

DALLAS (AP) — A California couple in an escalating fight with their surrogate over a newborn with a life-threatening heart defect told a Texas court Tuesday that the child's condition has worsened and they are anguished by attempts to deny them parental rights because they previously wanted an abortion. “He's our child,” Nausheen Gilkar said, wiping away tears on the witness stand. “She's unstable,” Gilkar said of surrogate McKenna West, who was sitting across from her in the Dallas courtroom. “She's trying to take him from us.” The hearing offered the fullest public airing to date of a deepening and high-profile dispute over surrogacy and abortion that has rushed right-to-life groups and GOP officeholders to the side of West, a nurse who flew from Alaska to have the baby on Aug. 12 in Texas, where most abortions are banned.

Related Stories